NeuroLex Labs
AI-powered voice analysis for early health condition detection.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
N/A | Acquisition | ||
| Total Funding | 000k | ||
NeuroLex Laboratories, operating as NeuroLex Diagnostics, was a digital health company founded in 2016 by Jim Schwoebel, Drew Morris, and James Fairey. The firm specialized in applying speech analysis and machine learning to detect health conditions early, focusing on neurological and psychotic disorders such as Depression, Schizophrenia, and Parkinson's Disease. Founder Jim Schwoebel, a biomedical technology expert in neurosciences, was inspired to start the company by his brother's experience with treatment-resistant schizophrenia and studies showing language patterns can reveal health data.
The company's core business involved providing a tool for physicians to screen patients by analyzing speech samples for health abnormalities. Its primary product was SurveyLex, a web-based platform that enabled the creation and distribution of voice surveys via URL links. This tool allowed NeuroLex to build a substantial biobank, which by August 2020, contained over 500,000 voice samples from more than 30,000 individuals, collected through partnerships with pharmaceutical companies and academic institutions. This extensive and labeled voice data was the company's key asset, utilized for modeling and analysis. The business operated in the decision/risk analysis and digital health markets, targeting healthcare providers and researchers.
In its early stages, NeuroLex secured $210K in a seed funding round in June 2017 from investors including Betaworks, CyberLaunch, MassChallenge, and others. A significant milestone occurred on August 25, 2020, when Sonde Health acquired NeuroLex Laboratories. The acquisition combined NeuroLex's web-based survey platform and extensive voice biobank with Sonde's mobile and voice-assistant platforms, aiming to create a comprehensive solution for voice-based health detection and monitoring. Following the acquisition, NeuroLex CEO Jim Schwoebel joined Sonde Health as Vice President of Data and Research. The current Neurolex.ai website describes an AI-powered platform connecting patients with mental health professionals, offering tools like AI journal analysis and secure communication. Keywords: vocal biomarkers, speech analysis, digital health, neurological disorders, mental health monitoring, health data acquisition, machine learning in healthcare, voice survey platform, clinical screening tools, psychiatric condition detection, biobank, voice data analysis, SurveyLex, Sonde Health, Jim Schwoebel, early disease detection, depression screening, schizophrenia screening, Parkinson's screening, decision analysis